Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis [0.03%]
代谢功能紊乱相关steatoohepatitis的当前和新兴治疗格局
Wenhao Li,William Alazawi,Rohit Loomba
Wenhao Li
Globally, metabolic dysfunction-associated steatotic liver disease (MASLD) is now the most common chronic liver disease, affecting up to one in three people in the general population, with an estimated increase in prevalence of more than 50...
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease [0.03%]
弥合中东和北非炎症性肠病临床试验中的代表性差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin et al.
Mohammad Shebab et al.
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
Stephanie A Vuijk
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial [0.03%]
mirikizumab治疗中至重度活动性溃疡性结肠炎儿科患者的有效性和安全性（SHINE-1）：一项多中心、开放标签、非随机Ⅱ期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner et al.
Jess L Kaplan et al.
Background: Mirikizumab, a humanised immunoglobulin G4 monoclonal antibody, targets the p19 subunit of IL-23, with demonstrated efficacy and safety in adults with ulcerative colitis and Crohn's disease. This study evaluat...
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity [0.03%]
呼吁对LGBTQIA+人群进行结直肠癌筛查以实现平等权益
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky et al.
Vidhi Singh et al.
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care [0.03%]
炎性肠病基本药物目录：是时候提高全球治疗标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein et al.
Nanne K de Boer et al.
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial [0.03%]
口服TNF和IL-23双特异性抑制剂SOR102在健康志愿者及溃疡性结肠炎患者中的安全性与药动学：一项随机、双盲、安慰剂对照的首次人体Ⅰ期临床试验
Vipul Jairath,Silvio Danese,Geert R D&#x;Haens et al.
Vipul Jairath et al.
Background: SOR102 is an oral bispecific antibody comprised of single domain antibodies targeting TNF and interleukin (IL)-23p19. We aimed to assess the safety, pharmacokinetics, clinical, and biological activity of SOR10...
Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis [0.03%]
一种双特异性抗体通过同时靶向TNF和IL-23治疗溃疡性结肠炎
Raja Atreya,Markus F Neurath
Raja Atreya
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy - Authors' reply [0.03%]
内镜医生面临的风险：暴露于结肠镜检查人工智能后的技能退化——作者的回复
Krzysztof Budzyń,Marcin Romańczyk,Yuichi Mori
Krzysztof Budzyń
Endoscopist deskilling risk after exposure to artificial intelligence in colonoscopy [0.03%]
内镜医生在结肠镜检查中接触人工智能后的技能下降风险
Davy van de Sande,Stefan Sleijfer,Stefan N R Buijsman et al.
Davy van de Sande et al.